Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors (Q33385120)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

Jean-Charles Soria

1

object named as

J-C Soria

0 references

Federico Cappuzzo

object named as

F Cappuzzo

7

0 references

Giuseppe Giaccone

object named as

G Giaccone

5

0 references

author name string

J-C Soria

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F A Shepherd

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J-Y Douillard

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Wolf

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Crino

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Sharma

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S H Gross

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Dimitrijevic

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Di Scala

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H Gardner

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Nogova

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

V Papadimitrakopoulou

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

23 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1674-1681

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

New targets for non-small-cell lung cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

mTOR and cancer: insights into a complex relationship

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Inhibitors of the mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP060

21 January 2018

Identifiers

10.1093/ANNONC/MDP060

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33385120&oldid=1984348889"